Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study by De Marchis, Gian Marco et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Copeptin adds prognostic information after ischemic stroke: results from the
CoRisk study
De Marchis, Gian Marco; Katan, Mira; Weck, Anja; Fluri, Felix; Foerch, Christian; Findling, Oliver;
Schuetz, Philipp; Buhl, Daniela; El-Koussy, Marwan; Gensicke, Henrik; Seiler, Marlen; Morgenthaler,
Nils; Mattle, Heinrich P; Mueller, Beat; Christ-Crain, Mirjam; Arnold, Marcel
Abstract: OBJECTIVE: To evaluate and validate the incremental value of copeptin in the prediction of
outcome and complications as compared with established clinical variables. METHODS: In this prospec-
tive, multicenter, cohort study, we measured copeptin in the emergency room within 24 hours from
symptom onset in 783 patients with acute ischemic stroke. The 2 primary end points were unfavor-
able functional outcome (modified Rankin Scale score 3-6) and mortality within 90 days. Secondary
end points were any of 5 prespecified complications during hospitalization. RESULTS: In multivariate
analysis, higher copeptin independently predicted unfavorable outcome (adjusted odds ratio 2.17 for any
10-fold copeptin increase [95% confidence interval CI, 1.46-3.22], p < 0.001), mortality (adjusted hazard
ratio 2.40 for any 10-fold copeptin increase [95% CI, 1.60-3.60], p < 0.001), and complications (adjusted
odds ratio 1.93 for any 10-fold copeptin increase [95% CI, 1.33-2.80], p = 0.001). The discriminatory ac-
curacy, calculated with the area under the receiver operating characteristic curve, improved significantly
for all end points when adding copeptin to the NIH Stroke Scale score and the multivariate models.
Moreover, the combination of copeptin with a validated score encompassing both the NIH Stroke Scale
and age led to a net reclassification improvement of 11.8% for functional outcome and of 37.2% for mor-
tality. CONCLUSIONS: In patients with ischemic stroke, copeptin is a validated blood marker that adds
predictive information for functional outcome and mortality at 3 months beyond stroke severity and age.
Copeptin seems to be a promising new blood marker for prediction of in-hospital complications.
DOI: 10.1212/WNL.0b013e3182887944
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-81897
Akzeptierte Version
Originally published at:
De Marchis, Gian Marco; Katan, Mira; Weck, Anja; Fluri, Felix; Foerch, Christian; Findling, Oliver;
Schuetz, Philipp; Buhl, Daniela; El-Koussy, Marwan; Gensicke, Henrik; Seiler, Marlen; Morgenthaler,
Nils; Mattle, Heinrich P; Mueller, Beat; Christ-Crain, Mirjam; Arnold, Marcel (2013). Copeptin adds
prognostic information after ischemic stroke: results from the CoRisk study. Neurology, 80(14):1278-1286.
DOI: 10.1212/WNL.0b013e3182887944
NEUROLOGY MS ID#: NEUROLOGY/2012/463802 
Copeptin Adds Prognostic Information After Ischemic Stroke: 
Results From the CoRisk Study. 
De Marchis Gian Marco
1,2
, MD*; Katan Mira
2,3,4
, MD*, Ms; Weck Anja
1
, MD; Fluri 
Felix
3, 4
, MD; Foerch Christian
5
, MD; Findling Oliver
1
, MD; Schuetz Philipp
6
, MD, MPH; 
Buhl Daniela
1
, PhD; El-Koussy Marwan
1
, MD; Gensicke Henrik
4
, MD; Seiler Marlen
7
, PhD; 
Morgenthaler Nils
8
, MD, PhD, BMA; Mattle Heinrich P
1
, MD; Mueller Beat
6
, MD; Christ-
Crain Mirjam
4
, MD, PhD; Arnold Marcel
1
, MD.  
*These authors contributed equally to the manuscript 
1
Deps. of Neurology, Neuroradiology and Clinical Chemistry, Inselspital, University of Bern, 
Switzerland; 
2
Dep. of Neurology, College of Physicians and Surgeons, Columbia University, 
New York, US; 
3
 Dep. of Neurology, University Hospital of Zurich, Switzerland; 
4
Deps. of 
Neurology and Endocrinology, University Hospital of Basel, Switzerland; 
5
Dep. of 
Neurology, Goethe University, Frankfurt a. M., Germany;
 6
Medical University Clinic, 
Cantonal Hospital Aarau, Switzerland; 
7
Thermo Fisher Scientific, Hennigsdorf-Berlin, 
Germany; 
8
Dep. of Experimental Endocrinology, Charité, University Hospital Berlin, 
Germany.  
Contact information for the corresponding author: 
Marcel Arnold, MD 
Department of Neurology, University Hospital of Bern, Inselspital 
Freiburgstrasse 10 
3010 Bern – Switzerland 
Tel: +41 31 632 21 11 
Fax: +41 31 632 03 21 
marcel.arnold@insel.ch 
  
2 
Title Character count (with spaces): 79 
Abstract word count: 239 
Word count manuscript: 2976 
Number of references: 40 
Number of tables: 3 
Number of figures: 2 
Supplementary tables/figures: 5 supplemental tables (per reviewers’ request), 7 
supplemental figures (per reviewers’ request). 
Authors Contribution:  
As principal investigators, Dr De Marchis (GMDM), Dr Katan (MK) and Dr Arnold (MA) 
had full access to all the data in the study and take responsibility for the integrity of the data 
and the accuracy of the data analysis.  
Study concept and design: Katan, De Marchis, Christ-Crain, Mueller  
Acquisition of data: De Marchis, Weck, Fluri, Gensicke, Foerch, Findling 
Analysis and interpretation of data: De Marchis, Katan, Schütz, Arnold 
Drafting of the manuscript: De Marchis and Katan  
Critical revision of the manuscript for important intellectual content: Katan, De 
Marchis, Arnold, Christ-Crain, Mattle, Müller, Schuetz, Fluri, Foerch, Morgenthaler, Seiler, 
Weck, Findling, Gensicke, Buhl 
Obtained Funding: Katan, De Marchis, Christ-Crain, Arnold 
Administrative, technical or material support: De Marchis, Katan, Buhl, Morgenthaler, 
Seiler 
Study supervision: Katan and Arnold 
 
  
  
3 
Funding Sources: This study was supported by an unrestricted research grant from Thermo 
Fisher Scientific, Thermo Scientific Biomarkers, Clinical Diagnostics, Neuendorfstr. 25; 
16761 Hennigsdorf-Berlin (Germany); by the Clinical Trial Units of the University of Bern 
(Switzerland) through the De Quervain research grant for young clinical investigators; by the 
Foundation of the Inselspital Bern (Switzerland), by the Foundation Pro Scientia et Arte, 
Bern (Switzerland) and by the Swiss National Science foundation. All supporting entities had 
no role in the collection, management, analysis, and interpretation of the data; or the 
preparation, or approval of the manuscript.  
Disclosures: GMDM applied for and received the following research grants: peer reviewed 
De Quervain research grant for young clinical investigators of the Clinical Trial Units of the 
University of Bern (Switzerland); Grant of the Foundation of the Inselspital Bern 
(Switzerland); Grant of the Foundation Pro Scientia et Arte, Bern (Switzerland). Moreover, 
GMDM is supported in the frame of the Special Program for University Medicine (SPUM-
Grant 33CM30-124119) and of a Career Development Grant for junior investigators 
(PBBEP3_139388) funded by the Swiss National Science Foundation. MK applied and 
received a Career Development Grant from the Swiss National Science Foundation 
(PBZHP3_130982), a transatlantic career development award form the foundation Leduqc 
and received an unconditional research grant for the CoRisk study from Thermo Fisher 
Scientific, Thermo Scientific Biomarkers, Clinical Diagnostics, Neuendorfstr. 25; 16761 
Hennigsdorf-Berlin (Germany). MCC, BM, and PS received support from Thermo Fisher 
Scientific to attend meetings and fulfilled speaking engagements not related to the CoRisk 
study. BM serves as a consultant and receives research support from Thermo Fisher 
Scientific. MS is an employee of Thermo Fisher Scientific, the manufacturer of the copeptin 
assay. NGM has been an employee of Thermo Fisher Scientific until June 2011. All other 
authors reports no disclosures related to the present manuscript. 
Clinical Trial Registration Information: This study is registered in ClinicalTrials.gov, unique 
identifier NCT00878813, http://www.clinicaltrials.gov/ct2/show/NCT00878813. 
Key words: biomarker■ copeptin ■ stroke ■ prognosis ■ mortality ■ complications 
  
4 
Abstract 
Objective: To evaluate and validate the incremental value of copeptin in the prediction of 
outcome and complications as compared to established clinical variables. 
Methods: In this prospective, multicenter cohort study we measured copeptin in the 
emergency room within 24 hours from symptom onset in 783 patients with acute ischemic 
stroke. The two primary endpoints were unfavorable functional outcome (modified Rankin 
Scale score 3-6) and mortality within 90 days. Secondary endpoints were any of five pre-
specified complications during hospitalization. 
Results: In multivariate analysis, higher copeptin independently predicted unfavorable 
outcome (adjusted OR 2.17 for any 10-fold copeptin increase [95% CI, 1.46–3.22], P<0.001), 
mortality (adjusted HR 2.40 for any 10-fold copeptin increase [95% CI, 1.60–3.60], P<0.001) 
and complications (adjusted OR for any 10-fold copeptin increase 1.93 [95% CI, 1.33–2.80], 
P=0.001). The discriminatory accuracy, calculated with the area under the receiver operating 
characteristics curve, improved significantly for all endpoints when adding copeptin to the 
National Institute of Health Stroke Scale (NIHSS) score and the multivariate models. 
Moreover, the combination of copeptin with a validated score encompassing both the NIHSS 
and age led to a net reclassification improvement (NRI) of 11.8% for functional outcome and 
of 37.2% for mortality. 
Conclusions: In patients with ischemic stroke, copeptin is a validated blood marker that adds 
predictive information for functional outcome and mortality at three months beyond stroke 
severity and age. Copeptin appears as a new promising blood marker for prediction of in-
hospital complications. 
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Introduction 
Accurate and prompt prediction of functional outcome, mortality, and complications in 
patients with ischemic stroke are essential for patients, families, and clinicians. In this 
context, rapidly measurable and reliable blood biomarkers may refine clinical decision-
making. Several blood biomarkers have shown the potential to predict outcome after 
ischemic stroke. However, in order to be useful in clinical routine, blood biomarkers are 
expected to improve the prognostic accuracy of established clinical variables such as stroke 
severity and age.
1
 At present, either the investigated biomarkers have failed to further 
improve prognostication after stroke, or they have not been studied concerning their 
additional prognostic value.
1,2
 However, a recent single-center study showed that copeptin, a 
hypothalamic hormone derived from the precursor of vasopressin, predicted outcome and 
mortality three months and one year after ischemic stroke, improving the prognostic accuracy 
of established predictors.
3, 4
 Copeptin is a reliable prognostic marker not only in stroke 
patients but also in patients with cardiovascular events.
5, 6
 However, before implementing 
copeptin in clinical practice, the prognostic potential of copeptin needs to be validated in a 
prospective, independent, large multicenter study. Moreover, it is unclear whether copeptin 
predicts outcome in patients with ischemic stroke that has been treated differently, i.e. 
conservatively or with thrombolysis. The CoRisk study aimed to validate in a multicenter, 
international setting the accuracy of copeptin in predicting functional outcome, mortality, and 
complications as compared to established clinical variables.  
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Methods  
Ethics Statement 
This study (ClinicalTrials.gov: NCT00878813) was conducted according to the principles 
expressed in the Declaration of Helsinki and it was approved by the Ethics Committees. All 
patients or their welfare guardians provided written informed consent for the collection of 
data, blood samples, and subsequent analyses.  
Study design and cohort description 
The primary design of this multicenter prospective cohort study has been described in detail 
previously.
7
 For the analysis of this study we included 788 patients older than 18 years with 
an acute ischemic stroke within 24 hours of symptom onset, admitted consecutively to the 
emergency department of each tertiary care center between March 24, 2009 and April 8, 
2011.  
We defined acute ischemic stroke according to the World-Health-Organization Criteria as an 
acute focal neurological deficit lasting longer than 24 hours
8
 with no sign of acute 
intracranial bleeding on cerebral imaging. Exclusion criteria were missing informed consent 
or any diagnosis different from ischemic stroke (i.e. stroke mimics). Stroke physicians 
prospectively recorded the National Institute of Health Stroke Scale score (NIHSS)
9
 upon 
admission. The clinical stroke syndrome was assessed according to the Oxfordshire 
Community Stroke Project classification.
10
 Computed Tomography (CT) or Magnetic 
Resonance (MR) imaging was performed upon admission. MR imaging with diffusion-
weighted imaging (DWI) was performed in 537 stroke patients. DWI lesion volumes were 
measured by the consensus of two experienced raters unaware of the clinical and laboratory 
findings. The lesion size was calculated by a commonly used semi-quantitative method 
validated for ischemic stroke lesions.
11
 Lesions were categorized into three size classes to 
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represent typical stroke patterns: i) small lesion with a volume of < 10 mm
3
, ii) medium 
lesion of 10–100 mm3, iii) large lesion with a volume of more than 100 mm3.3  
Detailed information such as cardiac and neurovascular ultrasound and 24-hour ECGs 
were collected to define stroke etiology according to the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) classification.
12
 Comorbidities were assessed on admission by the 
modified Charlson-Comorbidity-Index.
13
  
Biomarker Measurement 
Blood was drawn in the emergency room, and within 24 hours of symptom onset, for all 
patients. After centrifugation for 20 minutes at 3’000g at room temperature, plasma (from 
EDTA tube) was aliquoted. Tubes were frozen locally at each center at –70C. Copeptin 
levels were assessed in plasma in a blinded batch-analysis by a new chemiluminescence-
sandwich-immunoassay. The lower detection limit was 0.4 pmol/l and the functional assay 
sensitivity was < 1 pmol/l (< 20% inter-assay coefficient of variation, defined as the ratio of 
the standard deviation to the mean). In 359 healthy individuals, median copeptin levels were 
reported to be 4.2 pmol/l with a 99th percentile of 13.5 pmol/l.
14
 
Ascertainment of Outcomes 
Trained stroke physicians and study nurses assessed outcome three months after the acute 
stroke, either during an outpatient visit (patients who underwent thrombolysis) or with a 
structured follow-up telephone interview. They were blinded to copeptin levels and baseline 
clinical variables.  
Primary Endpoints: The two primary endpoints were (1) unfavorable functional outcome 
(including mortality) defined as a modified Rankin Scale (mRS) score of 3 to 6, and (2) 
mortality within 90 days of hospital admission.  
Secondary Endpoint: The secondary outcome included any of the following pre-specified 7 
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complications during hospital stay: symptomatic intracerebral hemorrhage (sICH) according 
to the SITS-MOST criteria
15
 , space-occupying cerebral edema, pneumonia (defined as 
auscultatory respiratory crackles combined with body temperature ≥ 38 °C, purulent sputum, 
or positive chest x-ray), seizures (clinical diagnosis of focal and/or generalized seizure in a 
previously non-epileptic patient), or mortality within 10 days from stroke onset.  
Statistical Analysis 
Univariate Analysis: Statistical analysis was performed for the primary and the secondary 
endpoints separately. Discrete variables were expressed as counts (percentages) and 
continuous variables as means ± standard deviations (SD) or medians (interquartile range), 
depending on their distribution. The distribution of raw biomarker data was skewed. After log 
transformation with a base of 10, the distribution of the biomarker data approximated a 
normal distribution. Comparisons for categorical baseline measurements were performed by 
Fisher’s exact test and for continuous, not normally distributed baseline data, by the Mann-
Whitney-U test. For survival analysis, we stratified patients according to copeptin tertiles in 
Kaplan Meier curves and compared the groups by mean of the logrank test.  
Multivariate Regression Models: To assess the independent association of copeptin with 
functional outcome and time to fatal outcome within 3 months, we computed a multivariate 
logistic and cox regression model, respectively. We pre-specified that models were adjusted 
for NIHSS, age, and lesion size, modified Charlson Index
13
 and Total Anterior Circulation 
Stroke (TACS)
10
 based on the results of the previous derivation study.
3
 In addition, the final 
multivariate models included variables significantly associated with an unfavorable outcome 
or mortality in the univariate analyses. As patients with severe stroke tend to present earlier, 
time from symptom onset to blood collection was included in the final model.
16
 We report 
odds and hazard ratios (OR and HR) along with 95% confidence intervals as measure of 
association and uncertainty, respectively. OR and HR correspond to a one-unit increase in the 
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explanatory variable and to any 10-fold increase in copeptin, glucose or CRP levels (log-
transformed with a base of 10). Goodness-of-fit of the multivariate logistic and cox 
regression models were assessed with the Hosmer-Lemeshow test and with Groennesby and 
Borgan test, respectively.  
Interaction Analysis: We further included interaction terms to investigate if the predictive 
value of copeptin is modified by treatment status (conservative vs. thrombolysis), gender, 
age, stroke-severity (NIHSS 0–6; NIHSS 7–15; NIHSS > 15), time from symptom onset, 
blood collection (dichotomized at 4.5 hours), arterial hypertension, diabetes mellitus and 
atrial fibrillation. Selection of variables that were tested for interaction was based on 
biological plausibility on factors that might influence the prognostic value copeptin. NIHSS 
was categorized in order to represent clinically relevant stroke severity subgroups (mild, 
moderate and severe strokes), and time from symptom onset was dichotomized to represent 
the time window for intravenous thrombolysis.  
C-statistics: The discriminatory value of copeptin was assessed with the area under the 
receiver-operating-characteristic curve (AUC). The incremental discriminatory value of 
copeptin was tested by comparing the AUC of the NIHSS (nested model), our prespecified 
prognostic factor of reference
7
, with the AUC of the NIHSS and copeptin (whole model), as 
well as comparing the logistic and cox regression models without copeptin (nested models) to 
the same models with copeptin (whole models). For these comparisons of nested to whole 
models, we used the likelihood ratio test as recommended.
17
  
Reclassification Tables:  
For risk model of comparison, we employed the multivariate models described above. As 
recommended in the statistical literature 
18
, we calculated continuous (category-free) NRIs 
since our multivariate models of comparisons have no validated risk categories. To calculate 
category-based NRIs, we employed the validated prognostic index by König IR et al, 
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encompassing admission NIHSS and age. 
19
 Four risk categories were chosen: 0-5%, 5-10%, 
10-15%, >15%.  
Statistics were calculated using Stata Statistical Software: Release 12 (StataCorp LP, College 
Station, TX, 2011). For reclassification tables, we employed R version R 2.15.1 along with 
the PredictABEL package (version 1.2-1) available from CRAN repository (http:// cran.r-
project.org/). Testing was two-sided and P values less than 0.05 were considered to indicate 
statistical significance.  
Results 
Study Population 
From March 24, 2009 through April 8, 2011 we consecutively recruited 788 patients with 
ischemic stroke. Stroke treatment was conservative in 465 patients (59.4%), and 318 patients 
(40.6%) underwent thrombolysis. Follow-up was available in 783 patients (follow-up rate: 
99.6%). The detailed patient flow is outlined in Figure 1. 
The median age of the cohort was 71.0 years (IQR 60.5–80.0), and 38.1% of the 
patients were women. The most common cardiovascular risk factor was arterial hypertension, 
which was present in 68.8% of patients. At admission, the median NIHSS score was 6 (IQR 
3–13), and the median copeptin concentration was 14.2 pmol/l (IQR 5.9–46.5)(Table 1).  
Primary Endpoints 
(1) Prediction of Functional Outcome after Three Months 
A total of 300 (38.3%) patients had an unfavorable outcome after three months. Median 
copeptin concentration was more than three-fold higher in patients with unfavorable 
outcomes than in those with favorable outcomes (Table 1, Figure e-1). In the multivariate 
logistic regression model, higher copeptin concentrations independently predicted an 
  
11 
unfavorable outcome (adjusted OR for any 10-fold copeptin increase 2.17 [95% CI, 1.46–
3.22]). For instance, for a patient with a copeptin level of 30.0 pmol/l, the odds of 
unfavorable outcome are on average 2.17 times or 117% higher compared to a patient with a 
copeptin level of 3.0 pmol/l, after adjustment for the covariates included in the logistic 
regression model presented in table 2. The multivariate logistic model was well calibrated as 
assessed by the Hosmer and Lemeshow goodness-of-fit test (P=0.62).  
The discriminatory accuracy of copeptin, assessed with the area under the ROC curve, was 
0.71 (95% CI, 0.67–0.75). Copeptin significantly improved the discriminatory accuracy of 
the NIHSS and the multivariate logistic regression model both for an unfavorable functional 
outcome, defined as mRS 3-6, (Table 3, Figures e-2 through e-4) and disability, defined as 
mRS 3-5, (Table e-3). 
Copeptin improved classification of patients when added to the validated prognostic index of 
Koenig et al 
19
 with a categorical NRI of 11.8% (Table e-4). Among patients with a favorable 
outcome, a total of 11.8% were moved to lower risk categories, while a net of zero patients 
with an unfavorable outcome was correctly reclassified. Moreover, adding copeptin to the 
full model improved reclassification as evidenced by the continuous NRI of 46.8%. 
(2) Prediction of Mortality within Three Months after Stroke 
A total of 118 (15.1%) patients died within three months after stroke. The median copeptin 
concentration was more than five-fold higher in patients who died within three months as 
compared to survivors (58.8 pmol/l [IQR 23.0–141.0] vs. 11.7 pmol/l [IQR 5.6–35.1], 
P<0.001) (Table e-1, Figure e-1). Overall, Kaplan–Meier survival curves of patients stratified 
per copeptin tertiles differed (P<0.001, logrank test) (Figure 2). In the multivariate cox 
model, higher copeptin concentrations independently predicted mortality (adjusted HR for 
any 10-fold copeptin increase 2.40 [95% CI, 1.60–3.60], P<0.001) (Table 2). The 
multivariate cox model was well calibrated as assessed by the Groennesby and Borgan test 
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(P=0.35). The overall discriminative ability of copeptin to distinguish survivors from non-
survivors – assessed with the area under the ROC curve – was 0.75 (95% CI, 0.71–0.80) 
(Figures e-5 through e-7). Copeptin significantly improved the discriminatory accuracy of the 
NIHSS and the multivariate cox regression model (Table 3). These results were also 
confirmed in reclassification statistics where the categorical NRI of copeptin upon the 
validated prognostic index of Koenig et al was 37.2% (Table e-5). Among survivors, a net of 
33.0% were moved to lower risk categories, while a net of 4.2% of patients dead at three 
months were moved to higher risk categories. Moreover, adding copeptin to the multivariate 
model resulted in a continuous NRI of 64.5%. 
Interaction Analysis 
The predictive value of copeptin regarding functional outcome and mortality was consistent 
across all subgroups. We did not identify any significant effect modifiers. 
Secondary Endpoint: Prediction of Complications 
A total of 185 patients (23.6%) suffered from at least one of the five predefined 
complications during hospitalization. Median copeptin levels were more than three-fold 
higher in patients developing any of the pre-specified complications during hospitalization 
(39.9 pmol/l [IQR, 16.4–114.0] vs. 11.0 pmol/l [IQR, 5.3–32.5], P<0.001) (Table e-2). In the 
multivariate logistic model, copeptin independently predicted the occurrence of at least one 
complication (adjusted OR for any 10-fold copeptin increase 1.93 [95% CI, 1.33–2.80], 
P=0.001). Other significant predictors were the NIHSS and age. Copeptin improved the 
prognostic accuracy of the NIHSS (AUC change from 0.79 [95% CI, 0.76–0.83] to 0.80 
[95% CI, 0.77–0.84], P=0.001). We found no significant interaction between copeptin and 
each of the potentially effect-modifying variables used for the primary outcomes. Prediction 
of individual complications was associated with different OR for any 10-fold copeptin 
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increase: for sICH, OR 1.07 (95% CI, 0.45-2.53, P=0.89); for space-occupying cerebral 
edema, OR 2.85 (95% CI, 1.39-5.87, P=0.004); for pneumonia, OR 1.79 (95% CI, 1.16-2.76, 
P=0.009); for seizures, OR 1.20 (95% CI, 0.62-2.33, P=0.59); for mortality within 10 days 
from admission, OR 3.00 (95% CI, 1.67-5.39, P<0.001).  
Discussion 
In this prospective multicenter study, higher copeptin blood levels independently predicted 
functional outcome and mortality three months after ischemic stroke. Copeptin improved the 
discriminatory ability of the NIHSS and multivariate models as shown by an increase in the 
respective AUCs. Despite the modest size of the AUC increases, copeptin improved risk 
classification by 11.8% for functional outcome and by 37.2% for mortality compared to the 
validated prognostic index by König IR et al, encompassing NIHSS and age. 
19
 Moreover, 
copeptin improved reclassification compared to the multivariate models including 
demographic factors, cardiovascular risk factors, lesion size in MR, comorbidities, and 
admission laboratory variables such as CRP and glucose. The CoRisk study confirms and 
extends the conclusions of the previously published derivation study
3
. Further new findings 
are that (1) copeptin independently predicts complications, and (2) the prognostic ability of 
copeptin was consistent across subgroups including different acute treatments (conservative 
vs. thrombolysis). 
While several markers, such as NT-BNP,
5, 20, 21
 CRP,
21-24
 D-Dimers,
20, 25, 26
 Interleukin-6,
21, 24, 
27
 von Willebrand factor,
28, 29
 S-100β,30 and neuron specific enolase (NSE),31 have been 
associated with functional outcome or mortality, only a few biomarkers added to prognosis 
based on clinical assessment. None of these markers, however, were fully evaluated including 
assessment of accuracy (i.e. calibration by goodness-of-fit test), discriminatory ability (i.e. C-
statistics), reclassification improvement, and performance in an external validation study 
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according to the recommendations of the American Heart Association for studies evaluating 
biomarkers in cardiovascular research. 
32
  
Several prognostic models have been evaluated in the past years. Some of these models 
include information from MR
33 
or CT 
34 
, others are based mostly on clinical information 
such as comorbidities or stroke severity
35, 36,
 
37
. As reference for reclassification, we chose the 
prognostic index of König IR et al because of its validation for both functional outcome and 
mortality at 3 months along with its robust prognostic power arising from two easily 
accessible variables such as age and NIHSS.
19
 In order to be used in clinical routine, 
prognosis should be almost immediate and based only on a few variables, thus copeptin, 
which adds to the simple and highly accurate prognostic index by Koenig et al
19
 may be 
promising. Measurement of copeptin in the emergency setting (incubation time 30 minutes 
6
) 
may help physicians to more accurately inform patients and care givers upon the overall 
prognosis. Copeptin might help in early decision making on aggressiveness of care, potential 
new interventions, discharge planning and rehabilitation. In the setting of trials of new stroke 
therapies, it might also be valuable predict those with stroke recovery. For optimal risk 
stratification, it is crucial that prognostic information is available within the first hours from 
symptom onset and copeptin meets this demand. The pathophysiological mechanism relating 
copeptin with stroke outcome and mortality is only partially understood. Copeptin derives 
from a larger precursor peptide along with vasopressin (AVP) and is released in an equimolar 
ratio to AVP. The advantage of copeptin is that it is more stable in blood circulation and 
easier to measure compared to AVP. 
14
 The secretion of AVP can be stimulated through 
brainstem and limbic pathways triggered by different “stressors”, it seems to act as an 
endogenous barometer of integral homeostasis. Thus copeptin assesses the severity of 
damage beyond lesion size, the effect of age, gender, and measurable clinical impairment on 
admission. In addition AVP/copeptin might be associated with ACTH-induced 
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hypercortisolism, which is thought to potentiate ischemic neuronal injury, especially in the 
long run.
38
 Data from experimental studies imply that AVP plays a role in brain edema 
formation as blocking of AVP receptors attenuates brain edema in ischemic mice models.
39
 
 Some limitations merit attention. To assess complications, a time-to-event analysis 
would have been ideal. However, we were not able to document the exact time of onset of 
some complications, e.g. aspiration pneumonia, and we did not take into account the duration 
of hospitalisation. Moreover, this study was only powered for the combined endpoint of 
complications after stroke, but not to assess each complication separately: our subgroup 
analyses should be interpreted with caution and further studies are needed to elucidate the 
specific association with each of the assessed complications.  
In patients with ischemic stroke, copeptin is a validated blood marker that adds predictive 
information on functional outcome and mortality at three months beyond important clinical 
variables such as stroke severity and age. Copeptin appears as a promising blood marker for 
prediction of in-hospital complications. 
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Figure Legends 
Figure 1: Flowchart of patient enrollment and follow up. 
Figure 2: Kaplan–Meier survival estimates for patients stratified by copeptin tertiles. The 
numbers of patients at risk are indicated at multiple of 10 days. Overall, Kaplan–Meier 
survival curves of patients stratified per copeptin tertiles differed (P<0.001, logrank test)  
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Tables 
Table 1. Baseline Characteristics of All Patients, Stratified by Outcome 
 All Patients  
(n = 783) 
Favorable Outcome  
 ( n = 483) 
Unfavorable Outcome 
 (n = 300) 
P Value 
Demographic data        
Age, median (IQR), y 71.0 (60.5–80.0) 66.2 (58.0–76.0) 77.3 (68.3–83.2) <.001 
Women, n (%) 298 (38.1) 162 (33.5) 136 (45.3) 0.001 
Medical history, n (%)        
Hypertension 539 (68.8) 312 (64.6) 227 (75.7) 0.001 
Atrial fibrillation 153 (19.5) 77 (15.9) 76 (25.3) 0.002 
Current smoking 138 (17.6) 98 (20.3) 40 (13.3) 0.01 
Diabetes mellitus 125 (16.0) 59 (12.2) 66 (22.0) <.001 
Coronary heart disease 149 (19.0) 75 (15.5) 74 (24.7) 0.002 
Dyslipidemia 432 (55.2) 280 (57.8) 152 (50.7) 0.001 
Previous cerebrovascular event 152 (19.4) 86 (17.8) 66 (22.0) 0.16 
Modified Charlson Index 0 (0–1) 0 (0–1) 1 (0–2) <.001 
Kidney impairment* 174 (22.2) 82 (17.0) 92 (30.7) <.001 
Clinical data, median (IQR)        
NIHSS at admission (points) 6 (3–13) 4 (2–7) 13 (7–18) <.001 
Body Mass Index (kg/m
2
) 25.8 (23.2–28.4) 25.9 (23.4–28.7) 25.6 (22.6–27.8) 0.14 
OCSP        
TACS 158 (20.2) 35 (7.1) 123 (41.0) <.001 
PACS 291 (37.2) 191 (39.5) 100 (33.3) 0.09 
LACS 188 (24.0) 161 (33.3) 27 (9.0) <.001 
POCS 146 (18.6) 96 (19.9) 50 (16.7) 0.30 
Laboratory values, median (IQR)        
Copeptin (pmol/l) 14.2 (5.9–46.5) 9.6 (4.7–25.8) 32.2 (11.8–103.5) <.001 
Time to blood collection (hours)† 2.8 (1.7–5.0) 2.7 (1.7–4.6) 3.0 (1.6–5.7) 0.33 
Glucose (mmol/l) 6.3 (5.5–7.5) 6.0 (5.4–7.2) 6.7 (5.8–8.3) <.001 
CRP (mg/l) 3.0 (3.0–6.0) 3.0 (3.0–5.0) 3.0 (3.0–9.0) <.001 
Creatinine (mmol/l) 81.0 (69.0-95.0) 80.0 (69.0-92.0) 82.0 (69.0-100.0) 0.27 
eGFR (ml/min/1.73m
2
)
‡
 75.0 (60.9-91.9) 77.6 (64.7-92.8) 70.5 (55.4-90.1) <.001 
Lesion size on MR, DWI§        
None detected 39 (7.3) 32 (8.6) 7 (4.2) 0.07 
Small (1–10mm
3
) 233 (43.4) 197 (53.1) 36 (21.7) <.001 
Medium (10–100mm
3
) 205 (38.2) 128 (34.5) 77 (46.4) 0.02 
Large (>100mm
3
) 60 (11.2) 14 (3.8) 46 (27.7) <.001 
TOAST subtype, n (%)        
Large-vessel disease 110 (14.0) 64 (13.2) 46 (15.3) 0.46 
Cardioembolic 308 (39.3) 183 (37.9) 125 (41.7) 0.29 
Small-artery disease 45 (5.8) 40 (8.3) 5 (1.7) <.001 
Multiple causes 70 (8.9) 52 (10.8) 18 (6.0) 0.03 
Other known 29 (3.7) 17 (3.5) 12 (4.0) 0.85 
Undetermined  221 (28.2) 127 (26.3) 94 (31.3) 0.14 
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Footnote: mRS, modified Rankin scale; IQR, interquartile range, meaning range between the 
first and third quartile; NIHSS, National Institute of Health Stroke Scale; OCSP, Oxfordshire 
Community Stroke Project classification; TACS, Total Anterior Circulation Stroke; PACS, 
Partial Anterior Circulation Stroke; LACS, Lacunar Anterior Circulation Stroke; POCS, 
Posterior Circulation Stroke; CRP, C-reactive protein; eGFR, estimated glomerular filtration 
rate; MR, Magnetic Resonance; DWI, Diffusion Weighted Imaging; TOAST, Trial of Org 10172 
in Acute Stroke Treatment.12 
See the “Statistical Analysis” section for a description of this analysis. Because of rounding, 
percentages may not total 100.  
* Kidney impairment was defined as eGFR lower than 60ml/min/1.73m2. 40  
† Time to blood collection was calculated in hours from symptom onset (if known). 
‡ eGFR was estimated according to the Modification of Diet in Renal Disease (MDRD) 
Study.40  
§ Percentages refer to patients where information on DWI lesion was present (n = 537). Of 
the 537 patients undergoing an MR on admission, 371 had a favorable outcome (69.1%) and 
166 had an unfavorable outcome (30.9%) within 3 months from stroke. The definition of 
stroke required an acute focal neurological deficit lasting longer than 24 hours, suggestive of 
acute stroke, and with no sign of acute intracranial bleeding on cerebral imaging (Computed 
Tomography or Magnetic Resonance). A visible ischemic lesion on MR imaging was not 
required for the diagnosis of ischemic stroke. 
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Table 2. Multivariate Logistic Regression Analysis for Functional Outcome and Cox Regression Model for Mortality 
 Functional Outcome Mortality  
Predictors OR 95% CI P HR 95% CI P 
Age (per year) 1.07 1.04 – 1.09 <0.001 1.04 1.02 – 1.06 <0.001 
Hypertension 1.00 0.60 – 1.68 0.99 0.90 0.53 – 1.51 0.68 
Diabetes mellitus 1.69 0.88 – 3.26 0.12 1.78 1.03 – 3.11 <0.001 
Atrial fibrillation 0.69 0.39 – 1.22 0.20 1.14 0.66 – 1.96 0.64 
Modified Charlson Index (per point) 1.06 0.89 – 1.27 0.50 1.11 1.01 – 1.23 0.04 
Kidney Impairment† 1.17 0.69 – 1.99 0.55 1.36 0.86 – 2.16 0.19 
NIHSS at admission (per point) 1.14 1.09 – 1.21 <0.001 1.05 1.02 – 1.08 <0.001 
TACS 1.98 0.97 – 4.04 0.06 2.02 1.17 – 3.49 0.01 
Log10(Copeptin [pmol/l])* 2.17 1.46 – 3.22 <0.001 2.40 1.60 – 3.60 <0.001 
Log10(Glucose [mmol/l]) * 0.55 0.07 – 4.50 0.58 0.68 0.10 – 4.66 0.69 
Log10(CRP [mg/l])* 1.77 0.99 – 3.17 0.05 1.89 1.20 – 2.96 0.01 
Large DWI lesion (>100 mm3) 4.16 1.62 – 10.65 0.003 1.25 0.69 – 2.27 0.47 
Time from symptom onset to blood collection (per hour) 1.06 1.01 – 1.11 0.01 1.01 0.97 – 1.06 0.64 
Woman 1.06 0.66 – 1.71 0.80 NA NA – NA NA 
Medium DWI lesion (10–100 mm3) 1.31 0.80 – 2.14 0.28 NA NA – NA NA 
Unclear cause of stroke NA NA – NA NA 2.23 1.39 – 3.58 0.001 
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Footnote: Study acronyms are explained in the first footnote to Table 1, if not otherwise specified. OR, odds ratio; HR, hazard ratio; CI, 
confidence interval; CRP, C-reactive protein; NA, not applicable, meaning that the variable was not significantly associated with an unfavorable 
outcome or mortality in the respective univariate analysis. See the “Statistical Analysis” section for a description of this analysis. OR and HR 
refer to a one-unit increase in the explanatory variable and to any 10-fold increase in copeptin, glucose, and CRP (log-transformed with a base 
of 10). For example, the odds of an unfavorable outcome are on average 2.17 times or 117% higher in a patient with a copeptin level of 30.0 
pmol/l compared to a patient with a copeptin level of 3.0 pmol/l, after adjustment for the covariates included in the presented logistic 
regression model. † Kidney impairment was defined as eGFR lower than 60ml/min/1.73m2.40 Coronary heart disease and eGFR/creatinine were 
not included in the multivariate model because of collinearity with atrial fibrillation and kidney impairment, respectively. 
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Table 3. Area under the Curve for Selected Predictors of Functional Outcome and 
Mortality 
 
Functional Outcome 
Predictors ROC Area 95% CI P* 
Copeptin [pmol/l] 0.71 0.67 – 0.75 - 
NIHSS 0.81 0.78 – 0.84 
<0.001 
NIHSS + Copeptin [pmol/l] 0.83 0.80 – 0.86 
      
Model 1 0.86 0.84 – 0.89 
<0.001 
Model 1 + Copeptin [pmol/l] 0.87 0.85 – 0.90 
      
 
Mortality 
Predictors ROC Area 95% CI P* 
Copeptin [pmol/l] 0.75 0.71 – 0.80 - 
NIHSS 0.80 0.77 – 0.84 
<0.001 
NIHSS + Copeptin [pmol/l] 0.83 0.79 – 0.86 
      
Model 2 0.86 0.82 – 0.90 
<0.001 
Model 2 + Copeptin [pmol/l] 0.87 0.83 – 0.91 
      
 
Footnote: Model 1, multivariate logistic regression model presented in table 2. 
Model 2, cox regression model presented in table 2. * To test the statistical 
significance of the comparisons of nested vs. whole models, the likelihood ratio test 
was used as recommended.17
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Figures 
Figure 1 
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Figure 2 
 
 
